RACHEL KOZOL: Open Payments
NPI 1164567749 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$202 in 10 payments from 6 companies in 2025. Trend: 2023 $69 · 2024 $118 · 2025 $202
Food & beverage: $202
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 4 | $73 |
| ABBVIE INC. | 2 | $39 |
| Janssen Pharmaceuticals, Inc | 1 | $36 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| E.R. Squibb & Sons, L.L.C. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
Products named: ARISTADA, VRAYLAR, INVEGA SUSTENNA, UZEDY, COBENFY, ABILIFY MAINTENA, VIVITROL.
Industry payments across NE — which companies pay providers there.
